Insider · CIK 0001327442
James E Fickenscher
Files at ZYNE (Zynerba Pharmaceuticals, Inc.). First filing -, latest -.
In brief
James E Fickenscher files SEC Form 4 as CFO at ZYNE (Zynerba Pharmaceuticals, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; James E Fickenscher has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 10, 2023 | ZYNE Zynerba Pharmaceuticals, Inc. | UTender of shares Common Stock | -123,087 | - | - | 255,000 | Oct 11, 2023 |
| Oct 10, 2023 | ZYNE Zynerba Pharmaceuticals, Inc. | AGrant or award Common Stock | +170,000 | - | - | 425,000 | Oct 11, 2023 |
| Oct 10, 2023 | ZYNE Zynerba Pharmaceuticals, Inc. | UTender of shares Common Stock | -425,000 | - | - | 0 | Oct 11, 2023 |
| Oct 10, 2023 | ZYNE Zynerba Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -125,000 | - | - | 0 | Oct 11, 2023 |
Questions about James E Fickenscher
Answered from the filings on this page, as of the latest one.
Is James E Fickenscher buying or selling?
James E Fickenscher has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did James E Fickenscher's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James E Fickenscher has 0.
Where does James E Fickenscher file Form 4?
James E Fickenscher has filed Form 4 at ZYNE (Zynerba Pharmaceuticals, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.